QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

SPRY

QT68ARS Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
9.65
-0.25-2.53%
OverviewShort InterestFilings
SPRYQT68ARS Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
9.65-2.53%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-2.01
Insider Own-
Shs Outstand99.30M
Perf Week0.63%
Market Cap983.10MForward P/E-EPS next Y-0.96Insider Trans0.02%Shs Float-Perf Month34.59%
Enterprise Value1.06BPEG0.05EPS next Q-0.49Inst Own-Short Float-Perf Quarter16.97%
Income-197996802.00P/S9.93EPS this Y12.94%Inst Trans-Short Ratio-Perf Half Y-9.47%
Sales98.99MP/B16.03EPS next Y45.37%ROA-68.84%Short Interest-Perf YTD-17.17%
Book/sh0.61P/C-EPS next 5Y-ROE-153.61%52W High18.90 -48.94%Perf Year-34.89%
Cash/sh2.02P/FCF-EPS past 3/5Y-ROIC-85.03%52W Low6.66 44.89%Perf 3Y-
Dividend Est.-EV/EBITDA-5.49Sales past 3/5Y337.95% 36.08%Gross Margin77.10%Volatility3.55% 4.42%Perf 5Y-
Dividend TTM-EV/Sales10.66EPS Y/Y TTM-2673.62%Oper. Margin-204.49%ATR (14)0.58Perf 10Y-
Dividend Ex-Date-Quick Ratio4.77Sales Y/Y TTM12.36%Profit Margin-200.00%RSI (14)58.38Recom1.67
Dividend Gr. 3/5Y-Current Ratio4.94EPS Q/Q-74.29%SMA205.99%Beta1.74Target Price25.50
Payout0.00%Debt/Eq1.57Sales Q/Q187.50%SMA5012.67%Rel Volume1.37Prev Close9.90
Employees155LT Debt/Eq0.84EarningsAug 12SMA2002.83%Avg Volume1.66MPrice9.65
IPO DateDec 04, 2020Option/ShortYes / YesEPS/Sales Surpr.-15.09% 4.55%Net Debt/EBITDA-0.38Volume2,276,963Change-2.53%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-09-26ReiteratedNorthland Securities$25
Mar-10-26ReiteratedLeerink PartnersOutperform$18 → $26
Nov-04-25ResumedRoth CapitalBuy$30
Sep-26-25ReiteratedRaymond JamesStrong Buy$22 → $32
Aug-19-24InitiatedCantor FitzgeraldOverweight$30
Aug-13-24UpgradeRaymond JamesOutperform → Strong Buy$22
Jul-25-24InitiatedRaymond JamesOutperform$18
Mar-05-24UpgradeLeerink PartnersMarket Perform → Outperform$14 → $18
Sep-20-23DowngradeWilliam BlairOutperform → Market Perform
Dec-13-22InitiatedLeerink Partners$14
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1008489
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A222021
Gross Profit766469
Selling, General and Administrative Excl. Other2612300
Research and Development141320
Other Operating Expense4052
Operating Income-202-179-3
Interest Expense230
Unusual Expense
———
Non-Operating Income (Expense)-7-11-11
Net Income Before Taxes-198-1718
Income Taxes
000
Consolidated Net Income-198-1718
Net Income From Continuing Operations-198-1718
Net Income-198-1718
EPS (Recurring)-2.01-1.740.08
EPS (Basic, Before Extraordinaries)-2.01-1.740.08
EPS (Diluted)-2.01-1.740.08
EBITDA-193-1678
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio9.5513.73—
Gross Margin76.0076.1977.53
Operating Margin-202.00-213.10-3.37
Net Margin-198.00-203.578.99
Shares Outstanding999997
Market Capitalization9551,153—
Operating Lease Expense
———
Insider Trading Volume
$10.25$9.16$8.07$6.98$5.89● Close Price0.00M1.77M3.54M5.30M7.07MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Karas EricChief Commercial OfficerJun 12 '26Option Exercise1.5050,00075,000519,588Jun 12 12:00 AM
Karas EricChief Commercial OfficerJun 12 '26Sale10.0025,000250,00012,176Jun 12 12:00 AM
Fitzpatrick Alexander AChief Legal OfficerJun 12 '26Sale10.003,35533,55090,910Jun 12 12:00 AM
Dorsey BrianChief Operating OfficerNov 13 '25Option Exercise0.6443,65627,94032,617Nov 14 12:00 AM
Dorsey BrianChief Operating OfficerNov 13 '25Sale8.7121,828190,05010,789Nov 14 12:00 AM
Chakma JustinChief Business OfficerNov 12 '25Option Exercise0.8460,00050,400166,380Nov 14 12:00 AM
Chakma JustinChief Business OfficerNov 12 '25Sale8.87166,3801,476,1470Nov 14 12:00 AM
Lowenthal Richard EPRESIDENT AND CEOAug 21 '25Sale14.4950,000724,3451,196,494Aug 22 12:00 AM
Scott Kathleen D.Chief Financial OfficerAug 21 '25Option Exercise1.5025,00037,500739,830Aug 22 12:00 AM
Scott Kathleen D.Chief Financial OfficerAug 21 '25Sale15.0012,500187,50010,042Aug 22 12:00 AM
Tanimoto SarinaCHIEF MEDICAL OFFICERAug 20 '25Sale14.0937,656530,6261,247,447Aug 21 12:00 AM
Tanimoto SarinaCHIEF MEDICAL OFFICERAug 19 '25Sale14.0312,344173,1301,285,103Aug 21 12:00 AM
Karas EricChief Commercial OfficerJul 01 '25Sale16.9915,000254,86110,315Jul 03 12:00 AM
Karas EricChief Commercial OfficerJul 01 '25Option Exercise1.5030,00045,000544,588Jul 03 12:00 AM
Flynn James E10% OwnerJun 27 '25Sale18.46370,0746,831,5664,887,254Jul 01 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR